Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea

References

• HuberKBatesERValgimigliMAntiplatelet and anticoagulant agents in acute coronary syndromes: what is the current status and what does the future hold?Am Heart J201416861162125440788
   PubMed Web of Science ®Google Scholar
• AronowWSTreatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patientsJ Gerontol A Biol Sci Med Sci200358M927M93314570861
   PubMed Web of Science ®Google Scholar
• SmithJNNegrelliJMManekMBHawesEMVieraAJDiagnosis and management of acute coronary syndrome: an evidence-based updateJ Am Board Fam Med20152828329325748771
   PubMed Web of Science ®Google Scholar
• AmsterdamEAWengerNKBrindisRG2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol201464e139e22825260718
   PubMed Web of Science ®Google Scholar
• TraJEngelJvan der WulpIde BruijneMCWagnerCMonitoring guideline adherence in the management of acute coronary syndrome in hospitals: design of a multicentre studyNeth Heart J20142234635324980680
   PubMed Web of Science ®Google Scholar
• HassanYKassabYAbd AzizNAkramHIsmailOThe impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon dischargeJ Clin Pharm Ther2013389710023441979
   PubMed Web of Science ®Google Scholar
• HuberKGershBJGoldsteinPGrangerCBArmstrongPWThe organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directionsEur Heart J2014351526153224742888
   PubMed Web of Science ®Google Scholar
• O’GaraPTKushnerFGAscheimDD2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol201361e78e14023256914
   PubMed Web of Science ®Google Scholar
• JägerBFarhanSKallaKOne-year mortality in patients with acute ST-elevation myocardial infarction in the Vienna STEMI registryWien Klin Wochenschr201512753554226162464
   PubMed Web of Science ®Google Scholar
• YusufSTwo decades of progress in preventing vascular diseaseLancet20023602312114031
   PubMed Web of Science ®Google Scholar
• AllonenJNieminenMSLokkiMMortality rate increases steeply with nonadherence to statin therapy in patients with acute coronary syndromeClin Cardiol201235E22E2722961648
   PubMed Web of Science ®Google Scholar
• YanATYanRTTanMOptimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcomeAm Heart J20071541108111518035083
   PubMed Web of Science ®Google Scholar
• BiYGaoRPatelAEvidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) studyAm Heart J2009157509.e1–516.e119249422
   PubMed Web of Science ®Google Scholar
• GurmHSEagleKAUse of anticoagulants in ST-segment elevation myocardial infarction patients: a focus on low-molecular-weight heparinCardiovasc Drugs Ther200822596918165932
   PubMed Web of Science ®Google Scholar
• LeeHYCookeCERobertsonTAUse of secondary prevention drug therapy in patients with acute coronary syndrome after hospital dischargeJ Manag Care Pharm20081427128018439049
   PubMed Web of Science ®Google Scholar
• DoyleFDe La HarpeDMcGeeHShelleyEConroyRGender differences in the presentation and management of acute coronary syndromes: a national sample of 1365 admissionsEur J Cardiovasc Prev Rehabil20051237637916079646
   PubMedGoogle Scholar
• BirkheadJSWestonCLoweDImpact of specialty of admitting physician and type of hospital on care and outcome for myocardial infarction in England and Wales during 2004-5: observational studyBMJ20063321306131116705004
   PubMed Web of Science ®Google Scholar
• DanchinNCambouJPHananiaGImpact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registryAm Heart J20051501147115316338251
   PubMed Web of Science ®Google Scholar
• van der ElstMEBouvyMLde BlaeyCJde BoerAEffect of drug combinations on admission for recurrent myocardial infarctionHeart2007931226123017502329
   PubMed Web of Science ®Google Scholar
• TraJvan der WulpIAppelmanYde BruijneMCWagnerCAdherence to guidelines for the prescription of secondary prevention medication at hospital discharge after acute coronary syndrome: a multicenter studyNeth Heart J20152321422125884093
   PubMed Web of Science ®Google Scholar
• ChenHYSaczynskiJSLapaneKLKiefeCIGoldbergRJAdherence to evidence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: a systematic reviewHeart Lung20154429930825766041
   PubMed Web of Science ®Google Scholar
• VermeerNSBajorekBVUtilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practiceJ Clin Pharm Ther20083359160119138236
   PubMed Web of Science ®Google Scholar
• YetginTvan der LindenMMde VriesAGCurrent discharge management of acute coronary syndromes: data from the Rijnmond Collective Cardiology Research (CCR) studyNeth Heart J201422202724155103
   PubMed Web of Science ®Google Scholar
• KimJLeeELeeTSohnAEconomic burden of acute coronary syndrome in South Korea: a national surveyBMC Cardiovasc Disord2013135523924508
   PubMed Web of Science ®Google Scholar
• MoebusSBalijepalliCLöschCAge- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome: a cross-sectional studyCardiovasc Diabetol201093420696055
   PubMed Web of Science ®Google Scholar
• RedfernJHyunKChewDPPrescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New ZealandHeart20141001281128824914060
   PubMed Web of Science ®Google Scholar
• ChengCIChenCPKuanPLThe causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry)Clin Cardiol201033E40E4820552592
   PubMedGoogle Scholar
• JinatongthaiPKhaisombutNLikittanasombatKChaiyakunaprukNWatcharathanakijSNathisuwanSUse of the CRUSADE bleeding risk score in the prediction of major bleeding for patients with acute coronary syndrome receiving enoxaparin in ThailandHeart Lung Circ2014231051105824931064
   PubMed Web of Science ®Google Scholar
• SalemisNSOikonomakisILagoudianakisEEnoxaparin-induced spontaneous massive retroperitoneal hematoma with fatal outcomeAm J Emerg Med2014321559e1e324972961
   PubMed Web of Science ®Google Scholar
• CostopoulosCNiespialowska-SteudenMKukrejaNGorogDANovel oral anticoagulants in acute coronary syndromeInt J Cardiol20131672449245522989603
   PubMed Web of Science ®Google Scholar
• De CaterinaRHustedSWallentinLNew oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis-task force on anticoagulants in heart disease position paperJ Am Coll Cardiol2012591413142522497820
   PubMed Web of Science ®Google Scholar
• DeftereosSBourasGGiannopoulosGNovel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?Curr Clin Pharmacol2012719520822564121
   PubMedGoogle Scholar
• AlfredssonJRoeMTRisks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary interventionDrug Saf20153848149125829216
   PubMed Web of Science ®Google Scholar
• GanetskyVSHadleyDEThomasTFRole of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromesPharmacotherapy20143459060424338703
   PubMed Web of Science ®Google Scholar
• AlexanderJHLopesRDJamesSApixaban with antiplatelet therapy after acute coronary syndromeN Engl J Med201136569970821780946
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEWiviottSDRivaroxaban in patients with a recent acute coronary syndromeN Engl J Med201236691922077192
   PubMed Web of Science ®Google Scholar
• StegPGMehtaSRJukemaJWRUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeEur Heart J2011322541255421878434
   PubMed Web of Science ®Google Scholar
• OldgrenJBudajAGrangerCBDabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized double-blind, phase II trialEur Heart J2011322781278921551462
   PubMed Web of Science ®Google Scholar
• TricociPHuangZHeldCThrombin-receptor antagonist vorapaxar in acute coronary syndromesN Engl J Med2012366203322077816
   PubMed Web of Science ®Google Scholar